Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Galloflavin is a **small molecule inhibitor of lactate dehydrogenase (LDH)**, specifically targeting LDH isoforms A (LDH-A) and B (LDH-B)[3][5]. It acts **by inhibiting glycolysis and ATP production**, exerting anti-proliferative effects in various cancer cell lines including breast, colorectal, pancreatic, and endometrial cancer[1][2][5]. Galloflavin demonstrates anticancer activity by blocking cell proliferation, migration, and invasion, reducing colony formation, and suppressing the expression of tumor-related proteins such as c-Myc and P21[1]. In inflammatory microenvironments, galloflavin also **directly targets and inhibits NLRP3**, an inflammasome component involved in cancer progression, reducing the expression of pro-inflammatory cytokines (IL-6, TNF-α, IL-1β), and tumor growth in animal models[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on galloflavin.